Abstract
Pneumococcal surface protein A (PspA) is one of the most protective vaccine antigens against pneumococco in animal models. Thus, its use as a carrier in a polyssacharide conjugate vaccine would be a good strategy to increase the protection and coverage of conjugate vaccines. However, there are reports that anti-PspA antibodies present cross-reactivity with human cardiac myosin. This led t…